Your browser does not support JavaScript!

Matières premières

351 entreprises et organismes intervenants dans le domaine 'Matières premières', classés par activité.

Rejoignez la communauté
Une actualité de FierceBiotech a été ajouté(e)
Il y a 2 semaines

Merck KGaA, GSK pen $4.2B biobucks pact for next-gen Bavencio

Il y a 2 semaines
German Merck, already partnered up with Pfizer on their immuno-oncology drug Bavencio, is hitting up another Big Pharma for developmental work worth billions in biobucks for a next-generation I-O drug...
www.fiercebiotech.com
2 entreprises
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

EuroBiotech Report—Roche flop, EMA-Brexit, antibiotic R&D, Merck KGaA and Sylentis

Il y a 2 semaines
In this week's EuroBiotech Report, Roche stops Alzheimer's phase 3, EMA readies for relocation and U.K. pushes for antibiotic R&D incentives. ...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 3 semaines

Merck KGaA and Tencent ally on developing ‘AI doctors’ for China

Il y a 3 semaines
Merck KGaA has signed on to a collaboration with Chinese internet giant Tencent, focused on developing digital, artificial intelligence-based platforms to help increase access to healthcare services...
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Le 15/01/2019

FDA approves Abbott’s pea-sized implant for sealing congenital heart defects in premature newborns

Le 14/01/2019
Abbott has received FDA approval for its Amplatzer Piccolo Occluder, which the medtech giant describes as the world’s first implant designed for babies weighing as little as two pounds....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 04/01/2019

Merck bags global rights to NGM NASH drug, plans phase 2b trial

Le 03/01/2019
Merck has acquired the exclusive global rights to NGM Biopharmaceuticals’ treatment for NASH and Type 2 diabetes. The agreement gives Merck control of a drug designed to reduce liver fat content by...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 13/12/2018

Roche to develop new dMMR pan-cancer test for Merck’s Keytruda immunotherapy

Le 12/12/2018
If you can’t beat 'em, join 'em: Roche is teaming up with its immuno-oncology competitor Merck & Co. to develop a pan-cancer companion diagnostic test for its Keytruda therapy aimed at...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 10/12/2018

Merck KGaA taps Cyclica for AI-based screening of protein-drug interactions

Le 07/12/2018
Merck KGaA has licensed a cloud-based artificial intelligence proteome screening platform from the Toronto-based Cyclica....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de L'Usine Nouvelle
Le 26/11/2018

Merck mobilise 30 millions d'euros contre le diabète

Le 25/11/2018
Le laboratoire allemand Merck va construire une extension de son usine de Semoy (Loiret) pour 19 millions d'euros. Il vient d'achever un programme de 11 millions... - Quotidien des Usines
www.usinenouvelle.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 20/11/2018

Merck KGaA, Palantir form new JV aimed at breaking down cancer data silos

Le 19/11/2018
Merck KGaA is launching a new joint venture with the tech firm Palantir, built around a collaboration platform for cancer research and discovery....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 08/11/2018

SITC18: Merck highlights new LAG-3 and TIGIT data

Le 07/11/2018
The SITC conference kicks off today with a stack of new data on immuno-oncology drugs, including a first look at Merck & Co.’s early-stage drugs targeting LAG-3 and TIGIT....
www.fiercebiotech.com
Charger plus d'actualités